It is used in combination with trastuzumab and docetaxel in the treatment of HER2-positive metastatic breast cancer patients who have not previously received anti-HER2 therapy or chemotherapy, as well as neoadjuvant therapy for early breast cancer. Here, ERBB2 is linked to breast cancer.